OrsoBio is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat obesity and other severe metabolic disorders, including type 2 diabetes, NASH, and severe dyslipidemias. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/07/23 | $60,000,000 | Series A |
Eli Lilly and Company Enavate Sciences  Longitude Capital NuevaBio Samsara BioCapital | undisclosed |
| 09/06/24 | $67,000,000 | Series B |
Ascenta Capital Eli Lilly and Company Enavate Sciences Longitude Capital NuevaBio Samsara BioCapital Woodline Partners | undisclosed |
